Oncology News | pharmaphorum

News

Sofinnova closes new fund and backs a trio of new biotechs

Sofinnova Partners has raised €165m for its new biotech fund and backed three startups working on Alzheimer's, fibrotic diseases, and cell therapies.

News

AstraZeneca buys cell therapy biotech for up to $1bn

AstraZeneca plans to acquire Belgian in vivo cell therapy biotech EsoBiotec and has signed a pair of licensing deals with drug delivery firm Alteogen.

News

Taiho snaps up ADC partner Araris for up to $1.14bn

Taiho has reached a deal to buy Swiss biotech Araris, around 18 months after they started collaborating on antibody-drug conjugates for cancer.

News

AbbVie builds the case for ovarian cancer drug Elahere

AbbVie hopes for another lift to its fast-growing ovarian cancer drug Elahere with new survival data.

News

Sutro puts lead ADC on hold, cuts staff and changes CEO

Sutro has shelved its lead drug for ovarian cancer and turned its attention to three preclinical candidates in a major shake-up of its business.

News

Kelun-Biotech first to bag TROP2 approval in lung cancer

Kelun-Biotech wins first global regulatory approval - in China - for a TROP2-directed antibody-drug conjugate (ADC) in lung cancer.

Sofinnova closes new fund and backs a trio of new biotechs

AstraZeneca buys cell therapy biotech for up to $1bn

Taiho snaps up ADC partner Araris for up to $1.14bn

AbbVie builds the case for ovarian cancer drug Elahere

Sutro puts lead ADC on hold, cuts staff and changes CEO

Kelun-Biotech first to bag TROP2 approval in lung cancer

France 'first EU country to cover obesity drugs'

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks